ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,448.80
2.18%
Dow Jones
38,675.68
1.18%
Brent Oil
82.765
-1.03%
Bitcoin
62,943.86
6.46%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Durect Corp (DRRX) Quote

Durect Corp

Durect Corp (DRRX)

NASDAQ
1.16
0.17
(17.17%)
At close: May 03 4:00PM
Delayed by 15 minutes
1.03
0.04
( 4.04% )
After Hours: 6:08PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.03
Bid
1.04
Ask
1.15
Volume
177,793
0.9712 Day's Range 1.19
0.4703 52 Week Range 7.46
Market Cap
34.9M
Previous Close
0.99
Open
1.02
Last Trade
10
@
1.15
Last Trade Time
17:37:31
Financial Volume
$ 195,782
VWAP
1.1012
Average Volume (3m)
155,996
Shares Outstanding
29,828,891
Dividend Yield
-
PE Ratio
-1.26
Earnings Per Share (EPS)
-0.93
Revenue
8.55M
Net Profit
-27.62M

About Durect Corp

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeli... Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.durect.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Durect Corp is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DRRX. The last closing price for Durect was $0.99. Over the last year, Durect shares have traded in a share price range of $ 0.4703 to $ 7.46.

Durect currently has 29,828,891 shares outstanding. The market capitalization of Durect is $34.90 million. Durect has a price to earnings ratio (PE ratio) of -1.26.

DRRX Latest News

More News

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis PR Newswire CUPERTINO, Calif., April 30...

April 30 2024
PR Newswire (US)

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire CUPERTINO, Calif., March 27, 2024 - Ongoing Communication with FDA to Align...

March 27 2024
PR Newswire (US)

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif., March 20, 2024 CUPERTINO, Calif., March 20, 2024...

March 20 2024
PR Newswire (US)

Form 8-K - Current report

March 04 2024
Edgar (US Regulatory)

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada PR Newswire CUPERTINO, Calif., March 4, 2024 Partnership...

March 04 2024
PR Newswire (US)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 14 2024
Edgar (US Regulatory)

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire CUPERTINO, Calif., Feb. 7, 2024 CUPERTINO, Calif., Feb. 7, 2024 /PRNewswire/ -- DURECT...

February 07 2024
PR Newswire (US)

Form 8-K - Current report

December 22 2023
Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

December 01 2023
Edgar (US Regulatory)

Form 8-K - Current report

November 13 2023
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.103411.15907619250.92661.190.87733690.9586377CS
4-0.005-0.483091787441.0351.190.7235998270.8768817CS
120.296740.46093004230.73331.410.72351559961.02731003CS
26-1.67-61.85185185192.72.89050.47034481340.73363448CS
52-3.13-75.24038461544.167.460.47033452811.70096163CS
156-18.27-94.663212435219.319.30.47034692396.83378022CS
260-4.433-81.14589053635.463410.470378085215.53518088CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OMHOhmyhome Ltd
$ 0.8701
(54.27%)
3.75M
IMTEIntergrated Media Technology Ltd
$ 3.38
(9.39%)
4.31k
WRAPWrap Technologies Inc
$ 1.83
(8.28%)
6.23k
LGCBLinkage Global Inc
$ 3.17
(8.19%)
594
PPBTPurple Biotech Ltd
$ 0.57
(7.55%)
4.72k
AFIBAcutus Medical Inc
$ 0.105
(-27.44%)
639.12k
MMATMeta Materials Inc
$ 2.45
(-26.87%)
153.29k
DRRXDurect Corp
$ 1.03
(-11.21%)
1.76k
GWAVGreenwave Technology Solutions Inc
$ 0.058
(-10.22%)
2.92M
GRTXGalera Therapeutics Inc
$ 0.167
(-10.22%)
792.91k
CMCSAComcast Corporation
$ 38.74
(0.13%)
6.76M
OMHOhmyhome Ltd
$ 0.8701
(54.27%)
3.75M
FFIEFaraday Future Intelligent Electric Inc
$ 0.041
(0.24%)
3.31M
GWAVGreenwave Technology Solutions Inc
$ 0.058
(-10.22%)
2.92M
SQQQProShares UltraPro Short QQQ
$ 11.05
(-0.27%)
2.52M

DRRX Discussion

View Posts
MythicSphinx35 MythicSphinx35 6 hours ago
Deeper Dive into DUR-928 Hypothetical Scenario and Implications:
Transplant Counts: Let's assume that approximately half the transplants in the study were in patients who would have died without one. Recategorizing these patients as alive would change the results significantly.
Revised Mortality: Factoring those transplants into the 'alive' category would likely lower the observed mortality rates in both the larsucosterol groups and the SOC group, likely resulting in a statistically significant difference between them.
Stronger Endpoint: By recognizing the lifesaving power of transplants, the analysis becomes a better reflection of the overall effectiveness of larsucosterol in improving patient outcomes beyond simply postponing death.
Conclusion: In my opinion even though the results for 90-day mortality didn't quite reach statistical significance, they strongly suggest that larsucosterol has the potential to be a transformative therapy for alcohol-associated hepatitis. Recategorizing transplant patients as alive would likely solidify the statistical significance of the findings. This, coupled with the strong trends observed across other outcomes and the drug's favorable safety profile, presents a compelling case for further investigation and potential approval.
👍️0
MythicSphinx35 MythicSphinx35 2 days ago
Lets assume that liver transplant recipients in the study were categorized as alive instead of deceased. In my opinion it's very likely that the DUR-928 2b trial would have achieved a statistically significant difference in the 90-day mortality endpoint. Here's why:
Mortality Reduction: The initial results show a clinically meaningful reduction in 90-day mortality for both dosages:
41% reduction for the 30mg dose (p-value = 0.070)
35% reduction for the 90mg dose (p-value = 0.126)
Transplants as a Lifesaving Intervention: Liver transplants are performed in severe AH cases to prevent imminent death. Again in my opinion by including successful transplants in the "alive" category, we are essentially factoring in the positive impact larsucosterol could have on disease progression and the need for this critical intervention.
👍️0
glenn1919 glenn1919 2 months ago
DRRX................................................https://stockcharts.com/h-sc/ui?s=DRRX&p=W&b=5&g=0&id=p86431144783
👍️0
Swampy83 Swampy83 3 months ago
I want news!! I want $30, lol
👍️0
INFINITI INFINITI 6 months ago
Can we move this today
👍️0
INFINITI INFINITI 6 months ago
That’s what these A Hoes want you to believe so you can sell at A loss MM tricks
👍️0
INFINITI INFINITI 6 months ago
Owell
👍️0
Distantpulse Distantpulse 6 months ago
This pos is done……..forget about it. I lost a lot on this one.
👍️0
INFINITI INFINITI 6 months ago
Yeah something fishy going on here looks illegal to me
👍️0
INFINITI INFINITI 6 months ago
ANALYST RATING
Buy
3.00 Rating Score
UPSIDE/?DOWNSIDE
1,227.5% Upside
$34.25 Price Target
👍️0
INFINITI INFINITI 6 months ago
Why not ?
👍️0
DeafTrader2 DeafTrader2 6 months ago
Why ?
👍️0
INFINITI INFINITI 6 months ago
Good opportunity here $$$$
👍️0
INFINITI INFINITI 6 months ago
Cheapies
👍️0
INFINITI INFINITI 6 months ago
"The topline results from AHFIRM provide compelling evidence that administration of larsucosterol can reduce mortality at 90 days in this devastating disease," said James E. Brown, D.V.M., President and CEO of DURECT. "We have strong rationale to advance larsucosterol into a Phase 3 registration trial designed with adequate power to detect a statistically significant result using 90-day mortality as the primary endpoint. We look forward to meeting with the FDA to discuss next steps. Based on the strength of the clinical data generated to date, if approved, larsucosterol could save many patient lives. We extend our thanks to all the patients, families, clinical trial investigators, and staff across the multiple sites globally who have worked with the DURECT team to bring larsucosterol to this advanced stage."
👍️0
INFINITI INFINITI 6 months ago
Cat bounce here got some
👍️0
Youlie Youlie 11 months ago
Bullish price target.
Looking at the drug they are developing it’s either home run or nothing.

👍️0
Distantpulse Distantpulse 12 months ago
$44 price target. Lol

https://www.benzinga.com/quote/DRRX/analyst-ratings
👍️0
Distantpulse Distantpulse 1 year ago
100% agree. This will be a total loss for investors.
👍️0
Foxwoods Man Foxwoods Man 1 year ago
There is really nothing positive about a R/S in a penny stock. It always seems to get back to the pre split price and 90% of your investment is toast. $3.60 looks better but in reality only 36 cents compared to last week
👍️0
Distantpulse Distantpulse 1 year ago
1/10 RS. 100% loss incoming. Smfh!
👍️0
Jimmy Joe Jimmy Joe 2 years ago
Been not liking this company since I was told about it. They are just trying to buy time. Stick a fork in this POS.
👍️0
Foxwoods Man Foxwoods Man 2 years ago
The vote is mostly just symbolic since corporate has enough votes to pass what they want.

I have NEVER seen a stock selling for under a buck do well after a R/S....it just seems to eventually get back to the pre split price and you are minus 90% of your shares.

I also voted against it
👍️0
Distantpulse Distantpulse 2 years ago
I voted against the R/S. F them!!! Hope everyone does the same. Garbage…..
👍️0
Foxwoods Man Foxwoods Man 2 years ago
Yup....I just dumped my shares at a loss to salvage something
👍️0
Distantpulse Distantpulse 2 years ago
R/S incoming! F’in BS!!!!
👍️0
Jimmy Joe Jimmy Joe 2 years ago
.how do you let your share price get this low.

When you don't have much in the pipeline and you have novice investors falling for every stupid PR you put out there. SO glad I stayed away form DRRX. Total garbage.
👍️0
Distantpulse Distantpulse 2 years ago
What a garbage company…….how do you let your share price get this low.
👍️0
Distantpulse Distantpulse 2 years ago
How low are they gonna let this POS go?! My god……Smfh.
👍️0
Jimmy Joe Jimmy Joe 3 years ago
Pretty much puts everything in a nutshell. DRRX POS~!

Will be lucky to see $2 again.....

If in this play.... get out ...... or take the ride down.

Just my opinion.
👍️0
Distantpulse Distantpulse 3 years ago
What a POS this stock is!! Smh
👍️0
suissac suissac 3 years ago
The two big catalyst for me is: (1). The authorized share count was not increased to 600,000,000 shares, even though DRRX had the votes; that is very, very, interesting. (2) The quarterly filing was was moved up to 7/29/2021. Theses two catalyst, could pertain to a partnership or a buyout news pending. The ship is getting ready to sail, and the rocket is going to the moon. My Opinion!
👍️0
suissac suissac 3 years ago
I see why the stock price is down; all the Insiders are Filing Form 4 today and receiving stock at a very low price.
👍️0
JohnLocke101 JohnLocke101 3 years ago
I’ll take $3.49
👍️0
mitchgree mitchgree 3 years ago
WILL NOT MOVE OVER $3.5O
👍️0
Jimmy Joe Jimmy Joe 3 years ago
DRRX is going nowhere real fast. Bail and grab some $AMC.
👍️0
JohnLocke101 JohnLocke101 3 years ago
Durect Price Target Announced at $6.00/Share by HC Wainwright & Co.
👍️0
suissac suissac 3 years ago
DRRX: This CEO doesn't PR much.
👍️0
suissac suissac 3 years ago
The hogs are now fed; now we move up!
👍️0
suissac suissac 3 years ago
Three Conference's coming this March, start your engines!
👍️0
vwlibra vwlibra 3 years ago
Um... maybe?

https://towardsdatascience.com/effect-of-financial-statement-release-on-stock-prices-97932b2cb05

👍️0
suissac suissac 3 years ago
Will the 3/4/2021 10Q move the stock?
👍️0
vwlibra vwlibra 3 years ago
I think so. I bought a small block today and intend to sit on this for a bit.
👍️0
GolfFishSurf GolfFishSurf 3 years ago
8-K out yesterday, showing that the offering is done and closed. Anyone think this will start to rise now that the offering is over and done with?
👍️0
stet stet 3 years ago
Got 50K somewhat derisked and looking for an upside.
👍️0
RNsidersbuying RNsidersbuying 3 years ago
DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression

https://www.marketwatch.com/press-release/durect-corporation-announces-us-fda-approval-of-posimir-for-post-surgical-pain-reduction-for-up-to-72-hours-following-arthroscopic-subacromial-decompression-2021-02-02?siteid=bigcharts&dist=bigcharts&tesla=y

Any renewed interest? Anyone?
👍️0
whytestocks whytestocks 4 years ago
News: $DRRX Durect Corp (DRRX) Q2 2020 Earnings Call Transcript

Image source: The Motley Fool. Durect Corp   (NASDAQ: DRRX) Q2 2020 Earnings Call Aug 3, 2020 , 4:30 p.m. ET Operator Continue reading

Got this from DRRX - Durect Corp (DRRX) Q2 2020 Earnings Call Transcript
👍️0
whytestocks whytestocks 4 years ago
News: $DRRX DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs

CUPERTINO, Calif. , Aug. 3, 2020 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2020 and provided a corporate update. Total revenues were $25.8 million and net income was $14.3 million for the three ...

Read the whole news DRRX - DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs
👍️0
ClayTrader ClayTrader 4 years ago
* * $DRRX Video Chart 06-25-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 4 years ago
* * $DRRX Video Chart 05-12-2020 * *

Link to Video - click here to watch the technical chart video

👍️0

Your Recent History

NASDAQ
DRRX
Durect
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved